alzheimer

Grífols claims clinical trial suggests reduction in disease's progression 

Research center run by top Catalan cardiologist and US scientists make breakthrough that holds out hope for future treatment

Scientists at the Universitat Autònoma de Barcelona (UAB) have found that an alteration of a neuronal gene program plays an essential role in the first stages of Alzheimer's disease and have developed a gene therapy which is effective on mice. The Catalan study occupies the front page of 'The Journal of Neuroscience'. Researchers have identified a new mechanism that regulates the expression of genes in the brain which are essential for the function of neuronal circuits involved in learning and memory. According to the new study, which was carried out by Dr. Carlos Saura's group at the UAB's Institute of Neurosciences (Institut de Neurociències), the alteration of a gene program mediating neuronal transmission and survival may underlie memory loss at early pathological stages of Alzheimer's disease (AD).

The Catalan pharmaceutical company Grífols and Barcelona’s Alzheimer Treatment&Research Center of Fundació ACE – a family charity – have announced that they will run tests of a vaccine against this neurodegenerative illness from January 2014. It will target 365 Alzheimer’s patients at mild and moderate stages of the illness. The first investigation project that ACE’s centre will host is called Ambar. The 365 participants will be randomly divided into three treatment groups plus a fourth control group. The patients will come from 17 Spanish hospitals and 20 United States’ medical centres. From 1996, the ACE Foundation has evaluated more than 14,000 people, 47% of whom were diagnosed with Alzheimer’s. It has the largest bank of genetic data in Europe.

Researchers in Barcelona have discovered a new molecule in order to create a new medicine in the treatment of Alzheimer’s disease. Unlike others, the discovery works at several damaged places of the brain at the same time. The molecule inhibits the secretion of the B-amiloide protein, which is a contributory factor in the disease.

Research conducted on genetically modified mice opens a new field of study to prevent the progression of Alzheimer’s disease by removing the spread of the Tau protein. This protein is a cause of disease which accumulates in the entorhinal cortex, moving from one region to another.

The results of the research will be helpful to expand the knowledge on diseases related to the process of protein aggregation. Discovery of this might lead to the early detection of Alzheimer ’s disease. The research has found a way to precisely measure the effects that protein aggregation has on cell aging.

Researchers from the Institute of Biomedical Research of Bellvitge (IBIDELL) have shown how brain areas interact as if the person is resting or active. Networks active when resting should be deactivated when awake, but a dysfunction in this process may be behind some diseases. The study has been published in the journal ‘PLoS ONE’.

The Catalan pharmaceutical company is the world’s leader in blood-derived products. After expanding in the United States by purchasing Talecris, Grifols needed a larger headquarters. It moved to three interconnected buildings in Sant Cugat del Vallès, in Barcelona’s Metropolitan Area. From the new facilities, Grifols will investigate stem cells and Alzheimer’s.

Researchers from Barcelona’s Hospital Clínic find other indicators about the beginning of Alzheimer’s. They recommend using alternative biomarkers to get an early diagnosis.

The Catalan Ministry of Social Care calculates a total of 80,000 diagnosed Alzheimer’s disease patients in Catalonia, a number that is expected to double in the next 10 years. The Ministry is now promoting a new attention model for Alzheimer’s patients based on individualised therapy and family collaboration.